HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression

Leuk Res. 2007 Jul;31(7):921-9. doi: 10.1016/j.leukres.2006.09.017. Epub 2006 Oct 23.

Abstract

FLT3 mutations and cell-surface antigen were investigated in 29 DR-negative (DR(-)) M1/M2 AML samples in comparison with 30 DR-positive (DR(+)) M1/M2 AML samples. FLT3-ITD was detected in 59.3% and D835 was detected in 7.4% of the samples. The incidence of FLT3-ITD was higher in the DR(-) group (59.3%) than in the DR(+) group (17.9%; P=0.002). The DR(-) status was associated with the CD34(-) (82.8%), CD7(-) (92.9%) and CD45RO(+) status (76%). Our results indicated that FLT3 mutation is the most common gene alteration found in the DR(-) M1/M2 AML. These results are important for further characterizing this phenotypic AML entity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antigens, CD34 / metabolism
  • Antigens, CD7 / metabolism
  • Antigens, Surface / metabolism*
  • HLA-DR Antigens / metabolism*
  • Humans
  • Karyotyping
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / metabolism
  • Leukocyte Common Antigens / metabolism
  • Molecular Sequence Data
  • Mutation / genetics*
  • Oncogene Proteins, Fusion / genetics
  • Oncogene Proteins, Fusion / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA, Neoplasm / genetics
  • RNA, Neoplasm / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sequence Homology, Amino Acid
  • fms-Like Tyrosine Kinase 3 / genetics*
  • fms-Like Tyrosine Kinase 3 / metabolism

Substances

  • Antigens, CD34
  • Antigens, CD7
  • Antigens, Surface
  • HLA-DR Antigens
  • Oncogene Proteins, Fusion
  • RNA, Messenger
  • RNA, Neoplasm
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Leukocyte Common Antigens